Showing results (81-90 of 97) with videos related to
Sort By:
Pageof 10
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.Immunohorizons|January 16, 2023
Blood-Borne Microparticles Are an Inflammatory Stimulus in Type 2 Diabetes MellitusStephen R Thom, Veena M Bhopale, Awadhesh K Arya, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.JAMA|April 4, 2013
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trialVance G Fowler, Keith B Allen, Edson D Moreira, et al.Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.JAMA|November 29, 2016
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenOle-Erik Iversen, Maria Jose Miranda, Angels Ulied, et al.The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.Pageof 10